Matthew S. Zabriskie

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 366 citations · Full text

Medicine, Molecular Biology, Oncology +7

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 245 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 223 citations

Medicine, Molecular Biology, Oncology +14

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <i>ROS1</i> -Rearranged Lung Cancer

Alexander Drilon, Romel Somwar, Jacob P. Wagner et al. · Clinical Cancer Research · 2015 · 167 citations · Full text

Medicine, Oncology, Pharmacology +16

Age-related mutations and chronic myelomonocytic leukemia

Clinton C. Mason, Jamshid S. Khorashad, Srinivas K. Tantravahi et al. · Leukemia · 2015 · 141 citations · Full text

Life Sciences, Genetics, Hematology +14